PolypsEARTHSCANNCT05064124
Early DiAgnosis Real-Time Healthcare System for CANcer Trial
An observational study of Polyps and Adenoma Colon, run by University College, London at 1 site in United Kingdom.
Trial summary
The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Polyps, Adenoma Colon, Colorectal Polyp
- What is being tested?
- CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy
- Type of treatment
- Medical device
- How many people
- 420 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 18 Jul 2024to May 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy at UCLH
Who may be able to join
- Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy with an endoscopist participating in the study phase of the trial.
- Male and female participants aged 18 years or older at the time of informed consent.
- Participants able to comprehend, sign and date the written informed consent document to participate in the study.
Who cannot join
- Emergency and/or inpatient colonoscopies
- Participants with inflammatory bowel disease (IBD)
- Participants with current Colorectal Cancer (CRC)
- Participants with a contraindication for biopsy or polypectomy. These include:
- Participants who have not withheld medications pre-disposing to bleeding at time of colonoscopy as per local site /national guidelines.
- Participants with a history of haemostasis disorders (haemostasis disorders will include but will not be limited to: participants with haemophilia or other congenitally acquired clotting factor deficiencies, participants with cirrhosis with coagulopathy, participants known to have thrombocytopenia (<80,000 platelet/ul) and individuals with Von Willebrand's disease or other known platelet malfunction disorders)
- Participant is enrolled in another research study with an investigational medicinal product (IMP) or non-IMP that pre-disposes them to bleeding
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
University College London Hospitals NHS Foundation Trust
London, NW1 2PG
Manish Chand, MBBS FRCS PhD
About this study
The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Participants will either have a colonoscopy with the assistance of the CADDIE device characterisation AI system ("intervention group") or have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system ("control group"). The randomisation method of this trial will allocate enrolled participants to the "intervention" group and to the "control" group by a technique similar to flipping a coin.
Read the detailed description
The CADDIE system comprises a computer attached to the output of the endoscopy stack and a screen which shows the normal video output of the colon in real-time. Using artificial intelligence (AI) software, it highlights the characteristics of a polyp to help the endoscopist in their optical diagnosis of the polyp histology. Pressing on a foot pedal, which is connected to the computer, presents the information from the AI software to the user as an overlay on the endoscopy screen in text format.
The CADDIE device is capable of recording the video output of the colon in real-time irrespective of whether the CADDIE's AI system is active.
In the endoscopist recruitment phase, we will identify endoscopists expertise and experience in colonoscopy.
In the study phase of the trial, the endoscopist will be kept the same for the CADDIE and control arm. At the beginning of each procedure, participant information will be entered into an electronic system (Redcap) which will generate a random allocation into one of two arms. The CADDIE arm involves a colonoscopy assisted by the CADDIE AI system (i.e., AI software). The control arm is a colonoscopy without the CADDIE's polyp characterisation AI system (i.e., standard practice). Each endoscopist will have the CADDIE device present during all endoscopy lists and will record all procedures in both CADDIE and control arms. The CADDIE's polyp characterisation system (i.e., AI software) will only be active in the CADDIE arm. The recordings in the control arms will allow an extra post-hoc assessment of how CADDIE might have performed compared to the actual assessment by the endoscopist.
In both arms of the trial, for each polyp the endoscopist detects, they will:
- Measure the polyp size and capture images of the polyp: Polyps are to be measured using an instrument of known size. For polyps measured to be <10mm, the endoscopist will capture a still image of the polyp in both white light and Narrow Band Imaging (NBI) or equivalent imaging modality.
- Optically diagnose the polyp: The endoscopist will optically diagnosis polyps <10mm, stating whether the diagnosis is made with high or low confidence.
- Resect diminutive polyps: Management of rectosigmoid hyperplastic polyps will be standardised. Rectosigmoid polyps that are optically diagnosed as hyperplastic by the endoscopist will be resected/biopsied. If multiple rectal hyperplastic polyps are optically diagnosed by the endoscopist, a maximum of 5 will be resected/biopsied for histopathology.
- Label the polyp with unique ID: Each polyp resected (regardless of size) must be labelled according to instructions of the Specimen Handling SOP. Each unique polyp ID will be logged in chronological order on a per colonoscopy basis and sent for histopathology. Histopathology will be referenced as the ground truth for polyp diagnosis and characterisation.
- Complete documentation as per standard of care: Documentation will be made in the endoscopy report of polyp site, size, morphology, segmental Boston Bowel Preparation Score (BBPS). A photograph will also be taken of the caecum and stored in the endoscopy report.
- Complete the optical diagnosis case report form (CRF):
Populate the optical diagnosis CRF at the end of the procedure with the polyp ID of each polyp sample (regardless of size), their optical diagnosis of each polyp <10mm in size and whether their optical diagnosis was made with high or low confidence.
In the CADDIE arm, the endoscopist presses the foot pedal once they have frozen an image of the polyp in the endoscopy screen in narrow band imaging (NBI) mode. This will output the CADDIE's characterisation of the polyp. Using this information and the endoscopist's own assessment, the endoscopist will log an optical diagnosis of the polyp and the confidence of their diagnosis (high or low). In the control arm, the endoscopist optically diagnoses the polyps without CADDIE's polyp characterisation function. The optical diagnosis will be assessed against the polyp histopathology which will be referred as the ground truth. Post-hoc analysis of the recorded footage will allow for comparison with the CADDIE generated polyp characterisation.
Safety of the device will be assessed through monitoring of adverse events. Acceptability will be assessed through a qualitative questionnaire for the endoscopist, endoscopy nurse and participant in addition to measuring endoscopy markers such as caecal intubation time, procedural time, withdrawal time.
- Conditions
- Polyps, Adenoma Colon, Colorectal Polyp, Colon Polyp, Polyps of Colon
- Being tested
- CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy
- Keywords
- Artificial intelligence, Endoscopy, ADR
- Medical subject headings
- Polyps, Colonic Polyps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CADDIE - Computer Aided Detection and Diagnosis for Intelligent EndoscopyDevice
- CADDIE assisted polyp detection
- CADDIE assisted polyp characterisation
| Study group | Role | What they receive |
|---|---|---|
| CADDIE | Participants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system Receives: Device: CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy | |
| Control group | Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary objective of this study is to evaluate whether the CADDIE system improves endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps (≤5mm).
The primary endpoint will be the proportion of diminutive colorectal polyps optically diagnosed correctly by endoscopists (correct optical diagnoses divided by total number of diminutive polyps), expressed as a percentage, in the CADDIE arm compared to the control arm, with the polyp histopathology being referenced as the ground truth.
Measured: 1 year
Secondary outcomes (8)
To determine whether using the CADDIE system improves endoscopists accuracy in the optical diagnosis of diminutive polyps in the rectosigmoid area.
The endpoint will be the proportion of diminutive rectosigmoid colorectal polyps optically diagnosed correctly by endoscopists (correct optical diagnoses divided by total number of diminutive rectosigmoid polyps), expressed as a percentage, in the CADDIE arm compared to the control arm, with the polyp histopathology being referenced as the ground truth.
Measured: 1 year
To determine whether using the CADDIE system improves the negative predicator value (NPV) of endoscopists for optically diagnosing diminutive adenomatous polyps in the rectosigmoid area.
The endpoint will be the NPV in optically diagnosing rectosigmoid diminutive adenomas in the CADDIE arm compared to the control arm, with the polyp histopathology being referenced as the ground truth.
Measured: 1 year
To assess the concordance of colonoscopy surveillance intervals in the CADDIE arm determined using endoscopists optical diagnosis against histopathology derived surveillance intervals (ground truth).
The concordance of colonoscopy surveillance intervals in the CADDIE arm when using endoscopists CADDIE assisted OD in comparison to histopathology derived intervals (ground truth) - per patient analysis.
Measured: 1 year
To assess the concordance of colonoscopy surveillance intervals in the control arm determined using endoscopists optical diagnosis against histopathology derived surveillance intervals (ground truth).
The concordance of colonoscopy surveillance intervals in the control arm when using endoscopists OD without the CADDIE system in comparison to histopathology derived intervals (ground truth) - per patient analysis.
Measured: 1 year
To compare the accuracy of the colonoscopy surveillance intervals when the endoscopists uses the CADDIE system (CADDIE arm) compared to without the CADDIE system (control arm).
To compare the concordance of colonoscopy surveillance intervals against histopathology derived surveillance intervals (ground truth) in the CADDIE arm with the control arm (expressed as a percentage) - per patient analysis.
Measured: 1 year
To evaluate how the CADDIE system influences the endoscopists confidence in their OD.
Compare the rate of endoscopists high-confidence optical diagnosis when using the CADDIE system compared to without.
Measured: 1 year
Evaluate the safety of the CADDIE system in clinical application.
Frequency of adverse events based on maximum severity of event for each participant in each arm. Adverse events will be recorded at 30 days post-procedure.
Measured: 1 year
Assess the integration of the CADDIE system into the normal colonoscopy clinical workflow.
- Compare caecal intubation time in both arms of the study. ii) Compare caecal intubation rate in both arms of the study. iii) Endoscopist/endoscopy nurse/patient experience and acceptability of the CADDIE system assessed by qualitative questionnaire.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2021
- Study start18 Jul 2024
- Primary completionMay 2025 (estimated)
- Study completionMay 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PolypsStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 420 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manish Chand, MBBS FRCS PhD, Principal investigator, UCL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05064124
- Sponsor's protocol ID
- 143608
- Acronym
- EARTHSCAN
- Status last verified
- Dec 2024
- First submitted
- 8 Sep 2021
- Last updated
- 16 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Patients will be asked informed consent with the possibility to share the data
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early DiAgnosis Real-Time Healthcare System for CANcer Trial
- ClinicalTrials.gov ID
- NCT05064124
- Acronym / sponsor ID
- EARTHSCAN / 143608
- Conditions
- Polyps, Adenoma Colon, Colorectal Polyp, Colon Polyp, Polyps of Colon
- Keywords
- Artificial intelligence, Endoscopy, ADR
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 420 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Study start
- 18 Jul 2024 (actual)
- Primary completion
- May 2025 (estimated)
- Study completion
- May 2025 (estimated)
- First posted
- 1 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to assess whether the AI characterisation system of the CADDIE device improves the endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps in the bowel during colonoscopy. Participants will either have a colonoscopy with the assistance of the CADDIE device characterisation AI system ("intervention group") or have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system ("control group"). The randomisation method of this trial will allocate enrolled participants to the "intervention" group and to the "control" group by a technique similar to flipping a coin.
Detailed description
The CADDIE system comprises a computer attached to the output of the endoscopy stack and a screen which shows the normal video output of the colon in real-time. Using artificial intelligence (AI) software, it highlights the characteristics of a polyp to help the endoscopist in their optical diagnosis of the polyp histology. Pressing on a foot pedal, which is connected to the computer, presents the information from the AI software to the user as an overlay on the endoscopy screen in text format.
The CADDIE device is capable of recording the video output of the colon in real-time irrespective of whether the CADDIE's AI system is active.
In the endoscopist recruitment phase, we will identify endoscopists expertise and experience in colonoscopy.
In the study phase of the trial, the endoscopist will be kept the same for the CADDIE and control arm. At the beginning of each procedure, participant information will be entered into an electronic system (Redcap) which will generate a random allocation into one of two arms. The CADDIE arm involves a colonoscopy assisted by the CADDIE AI system (i.e., AI software). The control arm is a colonoscopy without the CADDIE's polyp characterisation AI system (i.e., standard practice). Each endoscopist will have the CADDIE device present during all endoscopy lists and will record all procedures in both CADDIE and control arms. The CADDIE's polyp characterisation system (i.e., AI software) will only be active in the CADDIE arm. The recordings in the control arms will allow an extra post-hoc assessment of how CADDIE might have performed compared to the actual assessment by the endoscopist.
In both arms of the trial, for each polyp the endoscopist detects, they will:
- Measure the polyp size and capture images of the polyp: Polyps are to be measured using an instrument of known size. For polyps measured to be <10mm, the endoscopist will capture a still image of the polyp in both white light and Narrow Band Imaging (NBI) or equivalent imaging modality.
- Optically diagnose the polyp: The endoscopist will optically diagnosis polyps <10mm, stating whether the diagnosis is made with high or low confidence.
- Resect diminutive polyps: Management of rectosigmoid hyperplastic polyps will be standardised. Rectosigmoid polyps that are optically diagnosed as hyperplastic by the endoscopist will be resected/biopsied. If multiple rectal hyperplastic polyps are optically diagnosed by the endoscopist, a maximum of 5 will be resected/biopsied for histopathology.
- Label the polyp with unique ID: Each polyp resected (regardless of size) must be labelled according to instructions of the Specimen Handling SOP. Each unique polyp ID will be logged in chronological order on a per colonoscopy basis and sent for histopathology. Histopathology will be referenced as the ground truth for polyp diagnosis and characterisation.
- Complete documentation as per standard of care: Documentation will be made in the endoscopy report of polyp site, size, morphology, segmental Boston Bowel Preparation Score (BBPS). A photograph will also be taken of the caecum and stored in the endoscopy report.
- Complete the optical diagnosis case report form (CRF):
Populate the optical diagnosis CRF at the end of the procedure with the polyp ID of each polyp sample (regardless of size), their optical diagnosis of each polyp <10mm in size and whether their optical diagnosis was made with high or low confidence.
In the CADDIE arm, the endoscopist presses the foot pedal once they have frozen an image of the polyp in the endoscopy screen in narrow band imaging (NBI) mode. This will output the CADDIE's characterisation of the polyp. Using this information and the endoscopist's own assessment, the endoscopist will log an optical diagnosis of the polyp and the confidence of their diagnosis (high or low). In the control arm, the endoscopist optically diagnoses the polyps without CADDIE's polyp characterisation function. The optical diagnosis will be assessed against the polyp histopathology which will be referred as the ground truth. Post-hoc analysis of the recorded footage will allow for comparison with the CADDIE generated polyp characterisation.
Safety of the device will be assessed through monitoring of adverse events. Acceptability will be assessed through a qualitative questionnaire for the endoscopist, endoscopy nurse and participant in addition to measuring endoscopy markers such as caecal intubation time, procedural time, withdrawal time.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CADDIE | – | Device: CADDIE - Computer Aided Detection and Diagnosis for Intelligent EndoscopyParticipants will have a colonoscopy with the assistance of the CADDIE device characterisation AI system |
| Control group | – | –Participants will have a colonoscopy in line with routine clinical practice i.e., without the CADDIE device characterisation AI system |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy at UCLH
Key inclusion criteria (3 listed)
- Participants scheduled to undergo a screening, surveillance or symptomatic colonoscopy with an endoscopist participating in the study phase of the trial.
- Male and female participants aged 18 years or older at the time of informed consent.
- Participants able to comprehend, sign and date the written informed consent document to participate in the study.
Key exclusion criteria (7 listed)
- Emergency and/or inpatient colonoscopies
- Participants with inflammatory bowel disease (IBD)
- Participants with current Colorectal Cancer (CRC)
- Participants with a contraindication for biopsy or polypectomy. These include:
- Participant is enrolled in another research study with an investigational medicinal product (IMP) or non-IMP that pre-disposes them to bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy1. CADDIE assisted polyp detection 2. CADDIE assisted polyp characterisation | Device | CADDIE |
Primary outcome
The primary objective of this study is to evaluate whether the CADDIE system improves endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps (≤5mm).
Time frame: 1 year
The primary endpoint will be the proportion of diminutive colorectal polyps optically diagnosed correctly by endoscopists (correct optical diagnoses divided by total number of diminutive polyps), expressed as a percentage, in the CADDIE arm compared to the control arm, with the polyp histopathology being referenced as the ground truth.
8 secondary outcomes
To determine whether using the CADDIE system improves endoscopists accuracy in the optical diagnosis of diminutive polyps in the rectosigmoid area.
Time frame: 1 year
To determine whether using the CADDIE system improves the negative predicator value (NPV) of endoscopists for optically diagnosing diminutive adenomatous polyps in the rectosigmoid area.
Time frame: 1 year
To assess the concordance of colonoscopy surveillance intervals in the CADDIE arm determined using endoscopists optical diagnosis against histopathology derived surveillance intervals (ground truth).
Time frame: 1 year
To assess the concordance of colonoscopy surveillance intervals in the control arm determined using endoscopists optical diagnosis against histopathology derived surveillance intervals (ground truth).
Time frame: 1 year
To compare the accuracy of the colonoscopy surveillance intervals when the endoscopists uses the CADDIE system (CADDIE arm) compared to without the CADDIE system (control arm).
Time frame: 1 year
To evaluate how the CADDIE system influences the endoscopists confidence in their OD.
Time frame: 1 year
Evaluate the safety of the CADDIE system in clinical application.
Time frame: 1 year
Assess the integration of the CADDIE system into the normal colonoscopy clinical workflow.
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2024.
- Individual participant dataSharing planned: Yes. Patients will be asked informed consent with the possibility to share the data
Related trials for Polyps
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Nasal Polyps
RecruitingObservational study
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Esophageal Neoplasm, Esophageal Polyp
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
RecruitingPhase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
RecruitingPhase 4
Biologics in Chronic Rhinosinusitis With Nasal Polyposis
Chronic Sinusitis, Nasal Polyps
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Manish Chand, MBBS FRCS PhD principal investigator
UCL
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polyps and Adenoma Colon, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sharon Cheung, MSc (02076795217, sharon.cheung@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary objective of this study is to evaluate whether the CADDIE system improves endoscopists accuracy in the optical diagnosis of diminutive colorectal polyps (≤5mm). (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2024.